Remix Therapeutics said it received positive preliminary results for the ongoing Phase 1 of its lead drug, REM-422, in ...
The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback